Consistent with our in vitro data, NCC_CDS1_X1_C1 and NCC_CDS2_C1 tumor explants from adavosertib-treated mice demonstrated a decrease in CDK1 phosphorylation (Y15) and increased PARP cleavage compared with vehicle control (Figure 4, E and F). Here, CDK1 is linked to neoplasm.